Elastic NV vs Eli Lilly And Co — how do they compare? Elastic NV trades at $62.86 (market cap $6.47B), while Eli Lilly And Co trades at $1,171 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 159.2× Elastic NV's market cap, and Eli Lilly And Co pays a 0.6% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | LLY | |
|---|---|---|
Market Cap | $6.47B | $1.03T |
Sector | Technology | Health |
52-Week High | $94.47 | $1.24K |
52-Week Low | $43.30 | $625.65 |
Enterprise Value | $5.69B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $62.84, up 0.83% on the day, with a bullish technical signal from moving averages. The company shows strong profitability metrics with a 76.07% gross margin and 21.14% net margin, though current earnings show a net loss. Recent news highlights Elastic Security achieving a 100% malware protection score (Business Wire, July 15, 2026), while multiple law firm investigations create headline risk.
The outlook is mixed: analyst consensus is strongly bullish with a $73 price target and no sell ratings, but high EV/EBITDA (164.13) suggests premium valuation. Key opportunities include consistent earnings beats and leadership in security markets, while risks include ongoing legal investigations and the transition to profitability from current net losses.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →